Compounds > tsao-t
Page last updated: 2024-12-06

tsao-t

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID65005
CHEMBL ID364136
CHEMBL ID1738875
MeSH IDM0202529

Synonyms (17)

Synonym
tsao-t
1-[(1r,3r,4r,5r)-6-amino-4-[tert-butyl(dimethyl)silyl]oxy-1-[[tert-butyl(dimethyl)silyl]oxymethyl]-8,8-dioxo-2,9-dioxa-8$l^{6}-thiaspiro[4.4]non-6-en-3-yl]-5-methyl-pyrimidine-2,4-dione
[1-[2',5'-bis-o-(tert-butyldimethylsilyl)-.beta.-d-ribofuranosyl]thymine]-(r)(ribo)-3'-spiro-5-(4-amino-1,2-oxathiole-2,2-dioxide)
141781-17-1
2,4(1h,3h)-pyrimidinedione, 1-(4-amino-9-(((1,1-dimethylethyl)dimethylsilyl)oxy)-6-((((1,1-dimethylethyl)dimethylsilyl)oxy)methyl)-1,7-dioxa-2-thiaspiro(4,4)non-3-en-8-yl)-5-methyl-, s,s-dioxide. (5r-(5alpha,6beta,8beta,9alpha))-
1-[(5r,6r,8r,9r)-4-amino-9-(tert-butyl-dimethyl-silanyloxy)-6-(tert-butyl-dimethyl-silanyloxymethyl)-2,2-dioxo-1,7-dioxa-2lambda*6*-thia-spiro[4.4]non-3-en-8-yl]-5-methyl-1h-pyrimidine-2,4-dione
chembl364136
[2'',5''-bis-o-(tert-butyldimethylsilyl)-b-d-ribofuranosyl]-3''-spiro-5''''-(4''''-amino-1'''',2''''-oxathiole-2'''',2''''-dioxide)thymine
[2'',5''-bis-o-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]-3''-spiro-5''''-(4''''-amino-1'', 2''-oxathiole-2'',2''-dioxide)thymine
bdbm50169035
CHEMBL1738875
wf66y930kh ,
unii-wf66y930kh
2,4(1h,3h)-pyrimidinedione, 1-((5r,6r,8r,9r)-4-amino-9-(((1,1-dimethylethyl)dimethylsilyl)oxy)-6-((((1,1-dimethylethyl)dimethylsilyl)oxy)methyl)-2,2-dioxido-1,7-dioxa-2-thiaspiro(4.4)non-3-en-8-yl)-5-methyl-
3QO9
Q27292602
1-[(5r,6r,8r,9r)-4-amino-9-[tert-butyl(dimethyl)silyl]oxy-6-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2-dioxo-1,7-dioxa-2lambda6-thiaspiro[4.4]non-3-en-8-yl]-5-methylpyrimidine-2,4-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Reverse transcriptase/ ribonuclease HHuman immunodeficiency virus type 1 BH10IC50 (µMol)1.20001.20001.20001.2000AID977608
Chain B, p51 RTHuman immunodeficiency virus type 1 BH10IC50 (µMol)1.20001.20001.20001.2000AID977608
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)2.96670.00011.076810.0000AID268623; AID268624; AID593599
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID593504Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593508Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593505Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593602Inhibition of HIV-1 reverse transcriptase K1001E and E138K mutant-mediated polymerization reaction after 30 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID619908Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID593702Ratio of IC50 for HIV-1 reverse transcriptase K1001E and E138K mutant to IC50 for HIV-1 wild type reverse transcriptase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593698Ratio of EC50 for HIV1 3B harboring reverse transcriptase Y181I mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID253508Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID593608Ratio of EC50 for HIV1 3B harboring reverse transcriptase N136A/Q/K mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593701Ratio of EC50 for HIV1 3B harboring reverse transcriptase G190E mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593612Ratio of EC50 for HIV1 3B harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID322454Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.
AID593603Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593611Ratio of EC50 for HIV1 3B harboring reverse transcriptase V179N mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID245976Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID593503Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID246287Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID619903Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID593599Inhibition of wild type HIV-1 reverse transcriptase-mediated polymerization reaction after 30 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID268624Inhibition of HIV1 reverse transcriptase RNA-dependent DNA polymerase activity2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
AID593610Ratio of EC50 for HIV1 3B harboring reverse transcriptase E138D mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593509Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593594Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593596Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID619904Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID593598Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID619906Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID593506Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID327202Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis and anti-HIV1 biological activity of novel 5''-ATSAO compounds.
AID619905Cytotoxicity against human CEM cells after 4 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID81255Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID619907Cytotoxicity against human HuH7 cells after 72 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
AID253510Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID593507Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID106589Concentration required to reduce human MT-4 cell viability by 50%.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID268626Inhibition of MT4 cell viability2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
AID322455Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of viral replication2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.
AID593595Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593601Inhibition of HIV-1 reverse transcriptase E138K mutant-mediated polymerization reaction after 30 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID245974Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID593609Ratio of EC50 for HIV1 3B harboring reverse transcriptase E138K mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID327203Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis and anti-HIV1 biological activity of novel 5''-ATSAO compounds.
AID268625Antiviral activity against HIV1 in MT4 cells2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
AID268623Inhibition of FLAG-p66/HIS-p51-mediated HIV1 reverse transcriptase dimerization2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
AID593606Ratio of EC50 for HIV1 3B harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID322456Cytotoxicity against human CEM cells2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.
AID246294Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID246295Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID327201Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis and anti-HIV1 biological activity of novel 5''-ATSAO compounds.
AID593600Inhibition of HIV-1 reverse transcriptase K101E mutant-mediated polymerization reaction after 30 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593699Ratio of EC50 for HIV1 3B harboring reverse transcriptase Y188H mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593510Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID235889Ratio of effective concentration to that of cytotoxic concentration against HIV-1 induced cytopathogenicity in MT-4 cells1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID593700Ratio of EC50 for HIV1 3B harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID246288Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID593604Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593597Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593607Ratio of EC50 for HIV1 3B harboring reverse transcriptase V106A mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID593605Ratio of EC50 for HIV1 3B harboring reverse transcriptase L100I mutant to EC50 for wild type HIV1 3B2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
AID253507Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's24 (53.33)18.2507
2000's19 (42.22)29.6817
2010's2 (4.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.91 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (8.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (91.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymine
[no description available]		7.9140pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		1.9910isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
benzophenone
benzophenone : The simplest member of the class of benzophenones, being formaldehyde in which both hydrogens are replaced by phenyl groups.		2.0410benzophenonesphotosensitizing agent;
plant metabolite
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.4220carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		4.1850cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		3.1110aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
thymidine
[no description available]		7.26420pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		210alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		210aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		210amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		210aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
uridine
[no description available]		7.26420uridinesdrug metabolite;
fundamental metabolite;
human metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		210amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		210amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		3.4920dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		3.0810adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		2.0110metal allergen;
nickel group element atom;
platinum group metal atom
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		3.0810pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		210glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
alovudine
[no description available]		3.0810pyrimidine 2',3'-dideoxyribonucleoside
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		2.0410pseudohalide anionmitochondrial respiratory-chain inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.7830azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine
[no description available]		3.0810monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		3.1110acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
thymidine 5'-triphosphate
thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.		210pyrimidine 2'-deoxyribonucleoside 5'-triphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		2.6730aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)
1-(2',5'-bis-O-(tert-butyldimethylsilylribofuranosyl)-3-N-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide): structure given in first source; specific against HIV-1 replication		4.7290
methylthymidine
methylthymidine: RN given refers to N-3-methylthymidine		1.9810
2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd		2102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		1.98101,2,3-triazole
diprotin a
[no description available]		2.0310peptide
2'-c-methylcytidine
2'-C-methylcytidine: structure in first source		2.0610
r 82150
R 82150: structure given in first source; inhibits HIV-1 replication		2.3820
r-82913
R-82913: antiviral target on reverse transcriptase of HIV-1		2.6730
2',3'-dideoxyguanosine 5'-triphosphate
[no description available]		2.420
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.0610
HIV Coinfection
[description not available]		02.4220
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		02.0610
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.4220
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		07.0410
Acquired Immune Deficiency Syndrome
[description not available]		03.3120
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		03.3120